PURPOSE: Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical animal models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activities of rhIL-18 in patients with advanced cancer. EXPERIMENTAL DESIGN: Cohorts of patients were given escalating doses of rhIL-18, each administered as a 2-hour i.v. infusion on 5 consecutive days. Toxicities were graded using standard criteria. Serial blood samples were obtained for pharmacokinetic and pharmacodynamic measurements. RESULTS: Twenty-eight patients (21 with renal cell cancer, 6 with melanoma, and 1 with Hodgkin's lymphoma) were given rhIL-18 in doses ranging from 3 to 1,000 microg/kg. Common side effects included chills, fever, nausea, headache, and hypotension. Common laboratory abnormalities included transient, asymptomatic grade 1 to 2 neutropenia, thrombocytopenia, anemia, hypoalbuminemia, hyponatremia, and elevations in liver transaminases. One patient in the 100 microg/kg cohort experienced transient grade 3 hypotension and grade 2 bradycardia during the first infusion of rhIL-18. No other dose-limiting toxicities were observed. Plasma concentrations of rhIL-18 increased with increasing dose, and 2.5-fold accumulation was observed with repeated dosing. Biological effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes and monocytes. Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, IL-18 binding protein, and soluble Fas ligand were observed. Two patients experienced unconfirmed partial responses after rhIL-18 treatment. CONCLUSIONS: rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. A maximum tolerated dose of rhIL-18 was not determined. Further clinical studies of rhIL-18 are warranted.
PURPOSE:Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical animal models. A phase I study of recombinant humanIL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activities of rhIL-18 in patients with advanced cancer. EXPERIMENTAL DESIGN: Cohorts of patients were given escalating doses of rhIL-18, each administered as a 2-hour i.v. infusion on 5 consecutive days. Toxicities were graded using standard criteria. Serial blood samples were obtained for pharmacokinetic and pharmacodynamic measurements. RESULTS: Twenty-eight patients (21 with renal cell cancer, 6 with melanoma, and 1 with Hodgkin's lymphoma) were given rhIL-18 in doses ranging from 3 to 1,000 microg/kg. Common side effects included chills, fever, nausea, headache, and hypotension. Common laboratory abnormalities included transient, asymptomatic grade 1 to 2 neutropenia, thrombocytopenia, anemia, hypoalbuminemia, hyponatremia, and elevations in liver transaminases. One patient in the 100 microg/kg cohort experienced transient grade 3 hypotension and grade 2 bradycardia during the first infusion of rhIL-18. No other dose-limiting toxicities were observed. Plasma concentrations of rhIL-18 increased with increasing dose, and 2.5-fold accumulation was observed with repeated dosing. Biological effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes and monocytes. Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, IL-18 binding protein, and soluble Fas ligand were observed. Two patients experienced unconfirmed partial responses after rhIL-18 treatment. CONCLUSIONS: rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. A maximum tolerated dose of rhIL-18 was not determined. Further clinical studies of rhIL-18 are warranted.
Authors: Shivani Srivastava; David Pelloso; Hailin Feng; Larry Voiles; David Lewis; Zdenka Haskova; Margaret Whitacre; Stephen Trulli; Yi-Jiun Chen; John Toso; Zdenka L Jonak; Hua-Chen Chang; Michael J Robertson Journal: Cancer Immunol Immunother Date: 2013-04-19 Impact factor: 6.968
Authors: Michael J Robertson; Christopher W Stamatkin; David Pelloso; Jill Weisenbach; Nagendra K Prasad; Ahmad R Safa Journal: J Immunother Date: 2018-04 Impact factor: 4.456
Authors: K Manohar; P V Suneetha; Nirupama Trehan Pati; Abhishek C Gupta; Syed Hissar; Puja Sakhuja; S K Sarin Journal: Hepatol Int Date: 2009-03-17 Impact factor: 6.047
Authors: Michael J Robertson; Justin Kline; Herbert Struemper; Kevin M Koch; John W Bauman; Olivia S Gardner; Sharon C Murray; Fiona Germaschewski; Jill Weisenbach; Zdenka Jonak; John F Toso Journal: J Immunother Date: 2013 Jul-Aug Impact factor: 4.456
Authors: Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos Journal: Gynecol Oncol Date: 2009-12-02 Impact factor: 5.482
Authors: Ioannis Alagkiozidis; Andrea Facciabene; Carmine Carpenito; Fabian Benencia; Zdenka Jonak; Sarah Adams; Richard G Carroll; Phyllis A Gimotty; Rachel Hammond; Gwen-äel Danet-Desnoyers; Carl H June; Daniel J Powell; George Coukos Journal: J Transl Med Date: 2009-12-10 Impact factor: 5.531